Compare ANAB & SCZM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANAB | SCZM |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2015 | N/A |
| Metric | ANAB | SCZM |
|---|---|---|
| Price | $55.75 | $8.50 |
| Analyst Decision | Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $74.64 | N/A |
| AVG Volume (30 Days) | ★ 587.2K | 571.3K |
| Earning Date | 03-03-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $234,603,000.00 | N/A |
| Revenue This Year | N/A | $22.30 |
| Revenue Next Year | $33.49 | $69.17 |
| P/E Ratio | ★ N/A | $14.27 |
| Revenue Growth | ★ 157.01 | N/A |
| 52 Week Low | $15.40 | $6.90 |
| 52 Week High | $68.39 | $17.65 |
| Indicator | ANAB | SCZM |
|---|---|---|
| Relative Strength Index (RSI) | 42.55 | 43.34 |
| Support Level | $52.68 | $6.90 |
| Resistance Level | $57.70 | $8.63 |
| Average True Range (ATR) | 4.06 | 0.70 |
| MACD | -1.35 | 0.08 |
| Stochastic Oscillator | 8.37 | 50.15 |
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Santacruz Silver Mining Ltd is engaged in the operation, acquisition, exploration, and development of mineral properties in Latin America, with a primary focus on silver and zinc, including lead and copper. The company earns the majority of its revenue from Zinc and Silver. The company's reportable operating segments are the Bolivar mine and processing plant, the Porco mine and processing plant, the Caballo Blanco Group, San Lucas, Zimapan, and Corporate and Other activities. Key revenue is generated from Zimapan.